Repros Therapeutics Inc (RPRX)

[dendreonrich]

> However the fact that they did not specify yet what the specific endocrine endpoints are makes me a bit confused.

Last nights PR stated "Andre van As, M.D., PhD. Senior VP of Clinical and Regulatory Affairs of Repros, noted "Further analysis of the ZA 003 database has shown that there is a significant population of men who have elevated blood glucose; this population responded to Androxal(TM) therapy with a significant glucose reduction. An elevated blood glucose with a decreased testosterone has been associated with AIHH."

This suggests that the P3 trials will have T and blood glucose levels as the primary endpoints.